The Greater Cannabis Company, Inc. (GCAN)
OQB · Healthcare · Drug Manufacturers - Specialty & Generic
$0.17
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$156,008.77
Shares Outstanding
945K
Exchange
OQB
Currency
USD
About The Greater Cannabis Company, Inc.
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -48K | -37K | -54K | -33K |
| Net Income | -391K | -36K | 338K | -33K |
| Diluted EPS | $0.00 | $-0.04 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -177K | -175K | -156K | -183K |
| Net Income | -360K | -188K | -179K | -332K |
| Diluted EPS | $-0.00 | $0.00 | $0.00 | $0.00 |